Elucidating the constitutional genetic basis of multiple primary tumours

[1]  T. Dörk,et al.  Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations , 2014, Breast Cancer Research and Treatment.

[2]  Franco Berrino,et al.  Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. , 2007, The Lancet. Oncology.

[3]  Kris Chang,et al.  Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. , 2012, The New England journal of medicine.

[4]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[5]  M Ingelman-Sundberg,et al.  Cytochrome P450 pharmacogenetics and cancer , 2006, Oncogene.

[6]  B. Chain,et al.  The sequence of sequencers: The history of sequencing DNA , 2016, Genomics.

[7]  R. Burger,et al.  Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. , 2001, Gynecologic oncology.

[8]  M. Kloor,et al.  Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor , 2016, Familial Cancer.

[9]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[10]  N. Breslow,et al.  Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Allan,et al.  Mechanisms of therapy-related carcinogenesis , 2005, Nature Reviews Cancer.

[12]  Tom R. Gaunt,et al.  The UK10K project identifies rare variants in health and disease , 2016 .

[13]  S. Landolfo,et al.  Retroviruses and cellular oncogenes , 1989, The International journal of biological markers.

[14]  K. Hemminki,et al.  Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer , 2008, Breast Cancer Research and Treatment.

[15]  Jacek Majewski,et al.  ClinPred: Prediction Tool to Identify Disease-Relevant Nonsynonymous Single-Nucleotide Variants. , 2018, American journal of human genetics.

[16]  A. Coetzee,et al.  CASE REPORT AND REVIEW , 1974 .

[17]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[18]  P. Byrd,et al.  Modeling ATM mutant proteins from missense changes confirms retained kinase activity , 2009, Human mutation.

[19]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[20]  A. McKenna,et al.  Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity , 2013, Nature Genetics.

[21]  S. Steinberg,et al.  BHD mutations, clinical and molecular genetic investigations of Birt–Hogg–Dubé syndrome: a new series of 50 families and a review of published reports , 2008, Journal of Medical Genetics.

[22]  E. Maher,et al.  Cancer Genetics and Genomics , 2016 .

[23]  E. Baca-García,et al.  Association between smoking and alcohol use in the general population: stable and unstable odds ratios across two years in two different countries. , 2007, Alcohol and alcoholism.

[24]  J. Godino,et al.  A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes , 2002, Journal of medical genetics.

[25]  S. Narod,et al.  A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2. , 1998, American journal of human genetics.

[26]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[27]  D. Easton,et al.  Polygenic susceptibility to prostate and breast cancer: implications for personalised screening , 2011, British Journal of Cancer.

[28]  W. Linehan,et al.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment , 2014, Familial Cancer.

[29]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[30]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[31]  Donavan T. Cheng,et al.  Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. , 2016, JAMA oncology.

[32]  C. Nordling.  A New Theory on the Cancer-inducing Mechanism , 1953, British Journal of Cancer.

[33]  Nicola J. Rinaldi,et al.  Genetic effects on gene expression across human tissues , 2017, Nature.

[34]  S. Cross,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016, Journal of Medical Genetics.

[35]  Antonio L Amelio,et al.  Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. , 2017, Cancer cell.

[36]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[37]  F. Sanger,et al.  A Rapid Method for Determining Sequences in DNA by Primed Synthesis with DNA Polymerase , 1989 .

[38]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[39]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[40]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[41]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[42]  S. Gallinger,et al.  Motivations and psychosocial impact of genetic testing for HNPCC. , 2001, American journal of medical genetics.

[43]  C. Ricketts,et al.  Germline SDHB mutations and familial renal cell carcinoma. , 2008, Journal of the National Cancer Institute.

[44]  Rachael P. Huntley,et al.  QuickGO: a web-based tool for Gene Ontology searching , 2009, Bioinform..

[45]  H. Lynch,et al.  Hereditary cancer in adults. , 1995, Cancer detection and prevention.

[46]  M. Hegde,et al.  Multiple tumors in a child with germ-line mutations in TP53 and PTEN. , 2008, The New England journal of medicine.

[47]  A. López-Guillermo,et al.  POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia , 2013, Nature Genetics.

[48]  C. Tyler-Smith,et al.  Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. , 2016, Blood.

[49]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[50]  O. Schillaci,et al.  Incidental detection of colorectal cancer via 1(8)F-choline PET/CT in a patient with recurrent prostate cancer: usefulness of early images. , 2015, Clinical nuclear medicine.

[51]  P. Nowell,et al.  Discovery of the Philadelphia chromosome: a personal perspective. , 2007, The Journal of clinical investigation.

[52]  M. Greene,et al.  Developmental defects in gorlin syndrome related to a putative tumor suppressor gene on chromosome 9 , 1992, Cell.

[53]  Amar S. Ahmad,et al.  Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960 , 2015, British Journal of Cancer.

[54]  G. Romeo,et al.  A Cys634Gly substitution of the RET proto‐oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis , 1997, Clinical genetics.

[55]  J. Sicklick,et al.  Gastrointestinal stromal tumors in the setting of multiple tumor syndromes , 2014, Current opinion in oncology.

[56]  J. Cuzick,et al.  The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case–control study , 2016, Journal of Medical Genetics.

[57]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[58]  B. Vogelstein,et al.  Variation in cancer risk among tissues can be explained by the number of stem cell divisions , 2015, Science.

[59]  C. la Vecchia,et al.  Second primary cancers in patients with lung carcinoma , 1999, Cancer.

[60]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[61]  S. Seal,et al.  The ICR1000 UK exome series: a resource of gene variation in an outbred population , 2015, F1000Research.

[62]  Kory Jasperson,et al.  APC-Associated Polyposis Conditions , 2014 .

[63]  P. Rustin,et al.  Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. , 2014, Human molecular genetics.

[64]  Nancy F. Hansen,et al.  Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry , 2008, Nature.

[65]  Robert D. Finn,et al.  The Pfam protein families database: towards a more sustainable future , 2015, Nucleic Acids Res..

[66]  A. Magi,et al.  Detection of Genomic Structural Variants from Next-Generation Sequencing Data , 2015, Front. Bioeng. Biotechnol..

[67]  Tsviya Olender,et al.  GeneCards Version 3: the human gene integrator , 2010, Database J. Biol. Databases Curation.

[68]  D. L. Preston,et al.  Solid Cancer Incidence in Atomic Bomb Survivors: 1958–1998 , 2007, Radiation research.

[69]  D. Reintgen,et al.  Multiple primary melanomas: Implications for screening and follow-up programs for melanoma , 2006, Annals of Surgical Oncology.

[70]  Kari Stefansson,et al.  Sequence variants from whole genome sequencing a large group of Icelanders , 2015, Scientific Data.

[71]  Esti Yeger-Lotem,et al.  Role of duplicate genes in determining the tissue-selectivity of hereditary diseases , 2017, bioRxiv.

[72]  Aung Ko Win,et al.  Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. , 2013, Journal of the National Cancer Institute.

[73]  M. Cobleigh,et al.  Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient , 2017, Breast Cancer Research and Treatment.

[74]  L. Aaltonen,et al.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. , 2004, American journal of human genetics.

[75]  D. Dershaw,et al.  Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Urioste,et al.  Genetic Anticipation Is Associated with Telomere Shortening in Hereditary Breast Cancer , 2011, PLoS genetics.

[77]  Jing Wang,et al.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013 , 2013, Nucleic Acids Res..

[78]  A. Bolzán.  Effect of chemotherapeutic drugs on telomere length and telomerase activity , 2017 .

[79]  Th. Boveri.  Concerning the Origin of Malignant Tumours by Theodor Boveri. Translated and annotated by Henry Harris , 2008, Journal of Cell Science.

[80]  Rappold,et al.  Human Molecular Genetics , 1996, Nature Medicine.

[81]  D. Kerr,et al.  Implications of polygenic risk for personalised colorectal cancer screening. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[83]  Yoshimasa Horie,et al.  Birt-Hogg-Dubé syndrome and familial adenomatous polyposis: an association or a coincidence? , 2012, Internal medicine.

[84]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[85]  T. Milman,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2011 .

[86]  Bhramar Mukherjee,et al.  Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. , 2009, Gastroenterology.

[87]  S. Ezoe,et al.  Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor , 2012, International journal of environmental research and public health.

[88]  Doron Lancet,et al.  GeneHancer: genome-wide integration of enhancers and target genes in GeneCards , 2017, Database J. Biol. Databases Curation.

[89]  B. Haffty,et al.  Double Heterozygotes for Non‐Caucasian Families with Mutations in BRCA‐1 and BRCA‐2 Genes , 2006, The Breast Journal.

[90]  J. Casanova,et al.  Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants , 2014, Proceedings of the National Academy of Sciences.

[91]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[92]  William J. Astle,et al.  Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes , 2018, American journal of human genetics.

[93]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[94]  Jörg Hakenberg,et al.  Disease-associated variants in different categories of disease located in distinct regulatory elements , 2015, BMC Genomics.

[95]  M. Claustres,et al.  An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. , 2006, Human molecular genetics.

[96]  R. Eeles,et al.  Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations , 2005, Journal of Medical Genetics.

[97]  Kylie L. Gorringe,et al.  Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context , 2015, Scientific Reports.

[98]  P. Kantoff,et al.  Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.

[99]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[100]  C. Coutant,et al.  The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? , 2016, Oncotarget.

[101]  G. Giles,et al.  De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. , 1999, American journal of human genetics.

[102]  W. Foulkes,et al.  Germline truncating mutations in both MSH2 and BRCA2 in a single kindred , 2004, British Journal of Cancer.

[103]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[104]  P. Møller,et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.

[105]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[106]  Soo-Mi Park,et al.  Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review , 2017, The Journal of clinical endocrinology and metabolism.

[107]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[108]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Joseph K. Pickrell,et al.  A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes , 2012, Science.

[110]  Rodney J Scott,et al.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database , 2013, Nature Genetics.

[111]  Dorothy A. Thompson,et al.  Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. , 2017, American journal of human genetics.

[112]  Roy Parker,et al.  Nonsense-mediated mRNA decay: terminating erroneous gene expression. , 2004, Current opinion in cell biology.

[113]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[114]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  R. Hoover,et al.  New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. , 2006 .

[116]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[117]  Serena Nik-Zainal,et al.  Mechanisms underlying mutational signatures in human cancers , 2014, Nature Reviews Genetics.

[118]  W. Gilbert,et al.  A new method for sequencing DNA. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[119]  M. De Paola,et al.  Double heterozygosity in the BRCA1 and BRCA2 genes in Italian family , 2013, Clinical chemistry and laboratory medicine.

[120]  D. Sussman,et al.  Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing , 2017, Familial Cancer.

[121]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[122]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[123]  C. Hawkins,et al.  Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. , 2014, European journal of cancer.

[124]  J. Fraumeni,et al.  Multiple primary cancers in Connecticut, 1935-82. , 1986, The Yale journal of biology and medicine.

[125]  K. Klooster,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer , 2016 .

[126]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[127]  Jeong Eon Lee,et al.  Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients , 2011, Breast Cancer Research and Treatment.

[128]  S. Bojesen,et al.  Long telomeres and cancer risk among 95 568 individuals from the general population. , 2016, International journal of epidemiology.

[129]  Report of a family segregating mutations in both the APC and MSH2 genes: juvenile onset of colorectal cancer in a double heterozygote , 2008, International Journal of Colorectal Disease.

[130]  Geoff Der,et al.  Gender and telomere length: Systematic review and meta-analysis , 2014, Experimental Gerontology.

[131]  M. Carella,et al.  Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes. , 2014, Gene.

[132]  J. Toro.  Birt-Hogg-Dubé Syndrome , 2014 .

[133]  J. Burn,et al.  The role of aspirin in preventing colorectal cancer. , 2016, British medical bulletin.

[134]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[135]  David Haussler,et al.  Current status and new features of the Consensus Coding Sequence database , 2013, Nucleic Acids Res..

[136]  Electron Kebebew,et al.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[137]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[138]  D. Tripathy,et al.  Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .

[139]  N. Rahman,et al.  Update on the Manchester Scoring System for BRCA1 and BRCA2 testing , 2005, Journal of Medical Genetics.

[140]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[141]  Li Shang,et al.  Genomic and molecular characterization of esophageal squamous cell carcinoma , 2014, Nature Genetics.

[142]  M. Urioste,et al.  Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients , 2014, Breast Cancer Research and Treatment.

[143]  S. Purcell,et al.  Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring , 2003, Journal of medical genetics.

[144]  Soma Das,et al.  Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.

[145]  Li Ding,et al.  Patterns and functional implications of rare germline variants across 12 cancer types , 2015, Nature Communications.

[146]  R. Andersson.  Promoter or enhancer, what's the difference? Deconstruction of established distinctions and presentation of a unifying model , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.

[147]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[148]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[149]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[150]  Birgit Funke,et al.  Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.

[151]  P. Stenson,et al.  Human Gene Mutation Database (HGMD®): 2003 update , 2003, Human mutation.

[152]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[153]  D. Evans,et al.  Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening , 2007, Journal of Medical Genetics.

[154]  J. Lefèvre.  Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors , 2013 .

[155]  W. Foulkes,et al.  An evaluation of needs of female BRCA1and BRCA2 carriers undergoing genetic counselling , 2000, Journal of medical genetics.

[156]  Jane E. Carpenter,et al.  Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants , 2015, JNCI Journal of the National Cancer Institute.

[157]  D. Evans,et al.  Life expectancy in hereditary cancer predisposing diseases: an observational study , 2012, Journal of Medical Genetics.

[158]  J. Shendure,et al.  A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer , 2015, Nature Genetics.

[159]  J. Garber,et al.  Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch Syndrome , 2011, Familial Cancer.

[160]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[161]  T. Dörk,et al.  Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer , 2012, PloS one.

[162]  O. Díez,et al.  Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer , 2013, Breast Cancer Research and Treatment.

[163]  Josyf Mychaleckyj,et al.  Robust relationship inference in genome-wide association studies , 2010, Bioinform..

[164]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[165]  J. Yunis,et al.  Retinoblastoma and subband deletion of chromosome 13. , 1978, American journal of diseases of children.

[166]  S. Narod,et al.  An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2 , 2000, Clinical genetics.

[167]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[168]  K. Rauen,et al.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. , 2009, Current opinion in genetics & development.

[169]  P. Butow,et al.  Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review , 2003, The Medical journal of Australia.

[170]  Lior Pachter,et al.  VISTA: computational tools for comparative genomics , 2004, Nucleic Acids Res..

[171]  Semyon Kruglyak,et al.  Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms , 2013, Bioinform..

[172]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[173]  M. Tucker,et al.  Variation of second cancer risk by family history of retinoblastoma among long-term survivors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  S. Thibodeau,et al.  Multiple jejunal cancers resulting from combination of germline APC and MLH1 mutations , 2012, Familial Cancer.

[175]  I. Winship,et al.  Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes , 2007, Familial Cancer.

[176]  R. Gershoni-baruch,et al.  Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. , 1998, American journal of human genetics.

[177]  Beth Crawford,et al.  Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients , 2017, Breast Cancer Research and Treatment.

[178]  R. Whitehouse,et al.  Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls , 2017, Familial Cancer.

[179]  J. Burn,et al.  A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics , 2001, British Journal of Cancer.

[180]  Li Jia,et al.  Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. , 2015, The New England journal of medicine.

[181]  J. Norton,et al.  A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. , 2007, Cancer genetics and cytogenetics.

[182]  D. Evans,et al.  A clinical and genetic analysis of multiple primary cancer referrals to genetics services , 2014, European Journal of Human Genetics.

[183]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[184]  Iuliana Ionita-Laza,et al.  FUN-LDA: A Latent Dirichlet Allocation Model for Predicting Tissue-Specific Functional Effects of Noncoding Variation: Methods and Applications. , 2018, American journal of human genetics.

[185]  J. Lubiński,et al.  CHEK2 is a multiorgan cancer susceptibility gene. , 2004, American journal of human genetics.

[186]  A. Musolino,et al.  A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes , 2005, Breast Cancer Research and Treatment.

[187]  F. Langmark,et al.  Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. , 1994, Journal of the National Cancer Institute.

[188]  D. Livingston,et al.  Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer , 2013, Proceedings of the National Academy of Sciences.

[189]  D. Hodgson,et al.  Secondary breast cancer in Hodgkin's lymphoma survivors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  J. R. MacDonald,et al.  A copy number variation map of the human genome , 2015, Nature Reviews Genetics.

[191]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[192]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[193]  J. Benítez,et al.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.

[194]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[195]  C. Rubino,et al.  Long‐term risk of second malignant neoplasms after neuroblastoma in childhood: Role of treatment , 2003, International journal of cancer.

[196]  Caspar Zialor.  DNA sequencing with chain terminating inhibitors , 2014 .

[197]  J. Garber,et al.  Table 1. [Summary of Molecular Genetic Testing Used in Li-Fraumeni Syndrome]. , 2013 .

[198]  R. Peto,et al.  The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010 , 2011, British Journal of Cancer.

[199]  Wen J. Li,et al.  Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation , 2015, Nucleic Acids Res..

[200]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[201]  Justin K. Huang,et al.  A global transcriptional network connecting noncoding mutations to changes in tumor gene expression , 2018, Nature Genetics.

[202]  W. Jonat,et al.  Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management , 2012, Breast Cancer Research and Treatment.

[203]  J. Garber,et al.  Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. , 2006, Gastroenterology.

[204]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[205]  Timothy W. Smith,et al.  Interpersonal responses among sibling dyads tested for BRCA1/BRCA2 gene mutations. , 2008, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[206]  Elisa F. Long,et al.  Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making. , 2015, JAMA oncology.

[207]  P. Møller,et al.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.

[208]  D. Sgroi,et al.  Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. , 2002, Cancer research.

[209]  K. Hemminki,et al.  Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996 , 2001, International journal of cancer.

[210]  P. Loehrer.  Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship , 2008 .

[211]  A. Mortazavi,et al.  Genome-Wide Mapping of in Vivo Protein-DNA Interactions , 2007, Science.

[212]  S. Hancock,et al.  Gastrointestinal cancer after treatment of Hodgkin's disease. , 1997, International journal of radiation oncology, biology, physics.

[213]  K. Czene,et al.  Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family‐cancer database , 2002, International journal of cancer.

[214]  Leif Groop,et al.  LoFtool: a gene intolerance score based on loss‐of‐function variants in 60 706 individuals , 2016, Bioinform..

[215]  M. V. Filatov,et al.  The rare nonsense mutation in p53 triggers alternative splicing to produce a protein capable of inducing apoptosis , 2017, PloS one.

[216]  H. Møller,et al.  Radiation-induced malignancies following radiotherapy for breast cancer , 2004, British Journal of Cancer.

[217]  C. Eng,et al.  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations , 2012, Clinical Cancer Research.

[218]  Hermann Brenner,et al.  Multiple tumours in survival estimates. , 2009, European journal of cancer.

[219]  P. Hutter,et al.  Double frameshift mutations in APC and MSH2 in the same individual , 2006, International Journal of Colorectal Disease.

[220]  C. Pui,et al.  Second malignancy after treatment of childhood acute myeloid leukemia , 2001, Leukemia.

[221]  David M. Thomas,et al.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis , 2017, JAMA oncology.

[222]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[223]  M. Maranghi,et al.  Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family , 2011, Endocrine.

[224]  G. Lippi,et al.  BRCA population screening for predicting breast cancer: for or against? , 2017, Annals of translational medicine.

[225]  P. Goodfellow,et al.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer , 2017, JAMA oncology.

[226]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[227]  F. Crick,et al.  Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1974, Nature.

[228]  Peter L Choyke,et al.  Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. , 2005, American journal of human genetics.

[229]  M. Robson,et al.  Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications , 2012, Clinical Sarcoma Research.

[230]  A. Whittemore,et al.  The CHEK2*1100delC Allelic Variant and Risk of Breast Cancer: Screening Results from the Breast Cancer Family Registry , 2006, Cancer Epidemiology Biomarkers & Prevention.

[231]  S. Jewell,et al.  Copyright © American Society for Investigative Pathology Review Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids , 2022 .

[232]  R. Fisher.  On the Interpretation of χ2 from Contingency Tables, and the Calculation of P , 2010 .

[233]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[234]  John D Potter,et al.  Estimating the heritability of colorectal cancer. , 2014, Human molecular genetics.

[235]  A. Meadows,et al.  Abnormalities of chromosome #13 in retinoblastomas from individuals with normal constitutional karyotypes. , 1982, Cancer genetics and cytogenetics.

[236]  I. Tomlinson,et al.  Investigation of the Birt–Hogg–Dubé tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer , 2010, Journal of Medical Genetics.

[237]  S. Richard,et al.  Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN , 2008, Clinical Cancer Research.

[238]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[239]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[240]  Philipp Bucher,et al.  UCNEbase—a database of ultraconserved non-coding elements and genomic regulatory blocks , 2012, Nucleic Acids Res..

[241]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[242]  V. Wunderlich.  JMM — Past and Present , 2002, Journal of Molecular Medicine.

[243]  Jay Shendure,et al.  A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function. , 2018, American journal of human genetics.

[244]  M. Urioste,et al.  Concurrence of germline mutations in the APC and PTEN genes in a colonic polyposis family member. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[245]  B. Ponder,et al.  A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2 , 1997, Nature Genetics.

[246]  R. DePinho,et al.  Telomere dysfunction and evolution of intestinal carcinoma in mice and humans , 2001, Nature Genetics.

[247]  Anthony E. Reeve,et al.  E-cadherin germline mutations in familial gastric cancer , 1998, Nature.

[248]  S. Kitazawa,et al.  KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature. , 2007, International journal of andrology.

[249]  M. Simpson,et al.  Germline FH mutations presenting with pheochromocytoma. , 2014, The Journal of clinical endocrinology and metabolism.

[250]  B. Shuch,et al.  Krebs Cycle-Deficient Hereditary Cancer Syndromes are Defined by Homologous Recombination DNA Repair Defects , 2018, Nature Genetics.

[251]  S. Turner,et al.  Zero-Mode Waveguides for Single-Molecule Analysis at High Concentrations , 2003, Science.

[252]  K. Flanigan,et al.  Collagen Type VI-related disorders , 2012 .

[253]  M. Hurles,et al.  Somatic mutations reveal asymmetric cellular dynamics in the early human embryo , 2017, Nature.

[254]  X. Pivot,et al.  First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report. , 2017, Oncology reports.

[255]  M. Abdel-Rahman,et al.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers , 2011, Journal of Medical Genetics.

[256]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[257]  Qiang Feng,et al.  Identification of genomic alterations in oesophageal squamous cell cancer , 2014, Nature.

[258]  L. Aaltonen,et al.  Cancer risk in mutation carriers of DNA‐mismatch‐repair genes , 1999, International journal of cancer.

[259]  Yusuke Kobayashi,et al.  A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes , 2015, Breast Cancer.

[260]  Y. Nikiforov.  Radiation-induced thyroid cancer: What we have learned from Chernobyl , 2006, Endocrine pathology.

[261]  Martin Renqiang Min,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[262]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[263]  D. Schwartz,et al.  Pulmonary Fibrosis, Familial , 2015 .

[264]  V. Ramesh,et al.  Molecular analysis and prenatal diagnosis of human fumarase deficiency. , 1998, Molecular genetics and metabolism.

[265]  L. Strong,et al.  Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome , 2017, Clinical Cancer Research.

[266]  Daniel G. MacArthur,et al.  Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity , 2017, Nature.

[267]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[268]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[269]  H. Bayley,et al.  Continuous base identification for single-molecule nanopore DNA sequencing. , 2009, Nature nanotechnology.

[270]  Michael Dean,et al.  Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma Syndrome , 1996, Cell.

[271]  D. Evans,et al.  Nevoid basal cell carcinoma syndrome. , 1983, Canadian Medical Association journal.

[272]  D Morrell,et al.  Incidence of cancer in 161 families affected by ataxia-telangiectasia. , 1991, The New England journal of medicine.

[273]  P. Radice,et al.  Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics , 2010, Breast Cancer Research and Treatment.

[274]  Michael Worobey,et al.  The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues–Which Methods Are Useful When? , 2007, PloS one.

[275]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[276]  K. Brown,et al.  Assessment of PALB2 as a Candidate Melanoma Susceptibility Gene , 2014, PloS one.

[277]  R. Symons,et al.  Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[278]  S. Webb.  A Patient’s Journey : Xeroderma pigmentosum , 2008 .

[279]  I. Ceccherini,et al.  Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene. , 2008, European journal of endocrinology.

[280]  M. Tischkowitz,et al.  A germline mosaic BRCA1 exon deletion in a woman with bilateral basal‐like breast cancer , 2013, Clinical genetics.

[281]  J. Boyd,et al.  Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. , 1998, Gynecologic oncology.

[282]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[283]  H. Smith,et al.  A restriction enzyme from Hemophilus influenzae. I. Purification and general properties. , 1970, Journal of molecular biology.

[284]  Robert W. Taylor,et al.  Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency , 2012, Journal of Medical Genetics.

[285]  L. Travis,et al.  The Epidemiology of Second Primary Cancers , 2006, Cancer Epidemiology Biomarkers & Prevention.

[286]  K. Hemminki,et al.  Second primary cancers after sporadic and familial colorectal cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[287]  L. Guerrini-Rousseau,et al.  Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome , 2017, Journal of Medical Genetics.

[288]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[289]  K. Mullis,et al.  Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. , 1987, Methods in enzymology.

[290]  Marina T. DiStefano,et al.  Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion , 2018, Human mutation.

[291]  D. Evans,et al.  Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification , 2007, Journal of Medical Genetics.

[292]  S. Tommasi,et al.  Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report , 2010, Breast Cancer Research and Treatment.

[293]  Stephen Tanner,et al.  Canvas: versatile and scalable detection of copy number variants , 2016 .

[294]  L. Happerfield,et al.  Multilocus Inherited Neoplasia Alleles Syndrome: A Case Series and Review. , 2016, JAMA oncology.

[295]  S. Elgin,et al.  DNase I hypersensitive sites in Drosophila chromatin occur at the 5' ends of regions of transcription. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[296]  Lincoln D. Stein,et al.  Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma , 2017, JAMA oncology.

[297]  Naomichi Matsumoto,et al.  Precise detection of chromosomal translocation or inversion breakpoints by whole-genome sequencing , 2014, Journal of Human Genetics.

[298]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[299]  C. Eng,et al.  Germline mutations in PTEN and SDHC in a woman with epithelial thyroid cancer and carotid paraganglioma , 2007, Nature Clinical Practice Oncology.

[300]  G. Abecasis,et al.  Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. , 2012, American journal of human genetics.

[301]  D. Evans,et al.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes , 2005, Journal of Medical Genetics.

[302]  Jean-Marc Guinebretière,et al.  BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma , 2007, Familial Cancer.

[303]  F. Nielsen,et al.  Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutations , 2015, Familial Cancer.

[304]  W. Hunziker,et al.  Association of ARVCF with zonula occludens (ZO)-1 and ZO-2: binding to PDZ-domain proteins and cell-cell adhesion regulate plasma membrane and nuclear localization of ARVCF. , 2004, Molecular biology of the cell.

[305]  C. Sklar,et al.  Second cancers in survivors of childhood cancer , 2002, Nature Reviews Cancer.

[306]  T. Lange,et al.  Telomeres in cancer: tumour suppression and genome instability , 2017, Nature Reviews Molecular Cell Biology.

[307]  M. Levine,et al.  Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer , 2014, Breast Cancer Research and Treatment.

[308]  A. Vral,et al.  BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer , 2015, BMC Cancer.

[309]  D. Khayat,et al.  Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests , 2013, Breast Cancer Research and Treatment.

[310]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[311]  Dong Liang,et al.  PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS , 2016 .

[312]  Shannon M. Lynch,et al.  Race, Ethnicity, Psychosocial Factors, and Telomere Length in a Multicenter Setting , 2016, PloS one.

[313]  F. Loubser,et al.  Two double heterozygotes in a South African Afrikaner family: implications for BRCA1 and BRCA2 predictive testing , 2012, Clinical genetics.

[314]  Matthew B. Callaway,et al.  MuSiC: Identifying mutational significance in cancer genomes , 2012, Genome research.

[315]  I. Shuryak,et al.  Cancer Management and Research Dovepress Minimizing Second Cancer Risk following Radiotherapy: Current Perspectives , 2022 .

[316]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[317]  Mark E. Robson,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation , 2002 .

[318]  Soo-Mi Park,et al.  Tumour risks and genotype–phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD , 2018, Journal of Medical Genetics.

[319]  Pietro Liò,et al.  The BioMart community portal: an innovative alternative to large, centralized data repositories , 2015, Nucleic Acids Res..

[320]  E. Schröck,et al.  Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer , 2012, BMC Cancer.

[321]  L. J. Schelven,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group , 2004 .

[322]  V. Khoo,et al.  Radiotherapy for renal-cell carcinoma. , 2014, The Lancet. Oncology.

[323]  W. G. Feero,et al.  Clinical application of whole-genome sequencing: proceed with care. , 2014, JAMA.

[324]  G. Treglia,et al.  Incidental 11C-choline PET/CT uptake due to esophageal carcinoma in a patient studied for prostate cancer. , 2014, Clinical nuclear medicine.

[325]  A. Hagenbeek,et al.  Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. , 1995, Journal of the National Cancer Institute.

[326]  I. Lehman,et al.  Enzymatic synthesis of deoxyribonucleic acid. II. General properties of the reaction. , 1958, The Journal of biological chemistry.

[327]  M. Martino,et al.  Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities , 2011, Breast Cancer Research and Treatment.

[328]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[329]  L. Fallowfield,et al.  A qualitative study looking at the psychosocial implications of bilateral prophylactic mastectomy. , 2003, Breast.

[330]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[331]  D. Evans,et al.  Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey , 2015, Clinical genetics.

[332]  David Hogg,et al.  Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma , 1999, Nature Genetics.

[333]  S. Gruber,et al.  Relative frequency and morphology of cancers in STK11 mutation carriers. , 2004, Gastroenterology.

[334]  C. Lawton.  Breast Cancer Risk in Female Survivors of Hodgkin'S Lymphoma: Lower Risk After Smaller Radiation Volumes , 2010 .

[335]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[336]  T. Reinards,et al.  The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family , 2007, Familial Cancer.

[337]  E. Montgomery,et al.  Telomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis , 2004, Clinical Cancer Research.

[338]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[339]  F. Raue,et al.  Multiple Endocrine Neoplasia Type 2 , 2010 .

[340]  T. Shimosegawa,et al.  Telomere shortening and the clinicopathologic characteristics of human colorectal carcinomas , 1999, Cancer.

[341]  N. Slevin,et al.  What Three Wise Men have to say about diagnosis , 2011, BMJ : British Medical Journal.

[342]  D. Evans,et al.  Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome , 2013, The British journal of surgery.

[343]  A. V. van Kessel,et al.  The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery , 2016, Cellular Oncology.

[344]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[345]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[346]  E. Mercuri,et al.  Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues , 2017, Nucleic acid therapeutics.

[347]  S. Hinrichs,et al.  Structural evidence for the authenticity of the human retinoblastoma gene. , 1987, Science.

[348]  Xiaoyu Chen,et al.  Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..

[349]  M. Stratton,et al.  Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.

[350]  Rosalie E Ferner.  Neurofibromatosis 1 , 2010, European Journal of Human Genetics.

[351]  A. Lindblom,et al.  Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma , 2000, International journal of cancer.

[352]  P. Pharoah,et al.  Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.

[353]  A. Kasarskis,et al.  A window into third-generation sequencing. , 2010, Human molecular genetics.

[354]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[355]  J. Fraumeni,et al.  Second Cancers Following Radiotherapy for Cervical Cancer , 1983 .

[356]  Nazneen Rahman,et al.  Realizing the promise of cancer predisposition genes , 2014, Nature.

[357]  D. Sabatini,et al.  The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. , 2013, Molecular cell.

[358]  T. Skaar,et al.  High‐Throughput Assays to Assess the Functional Impact of Genetic Variants: A Road Towards Genomic‐Driven Medicine , 2017, Clinical and translational science.

[359]  O. Olopade,et al.  The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. , 2005, Gynecologic oncology.

[360]  H. Hollema,et al.  Rapidly progressive adenomatous polyposis in a patient with germline mutations in both the APC and MLH1 genes: the worst of two worlds , 2003, Gut.

[361]  R. Myers,et al.  Human Homolog of patched, a Candidate Gene for the Basal Cell Nevus Syndrome , 1996, Science.

[362]  L. Mullenders,et al.  Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects , 2008, Cell Research.

[363]  Peter Donnelly,et al.  Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas , 2013, Nature Genetics.

[364]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[365]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[366]  D. Horsman,et al.  Cytogenetic analysis of uveal melanoma consistent occurrence of monosomy 3 and trisomy 8q , 1993, Cancer.

[367]  I. Lehman,et al.  Enzymatic synthesis of deoxyribonucleic acid. I. Preparation of substrates and partial purification of an enzyme from Escherichia coli. , 1958, The Journal of biological chemistry.

[368]  Aviad E. Raz,et al.  Population screening for BRCA1/BRCA2 mutations: lessons from qualitative analysis of the screening experience , 2016, Genetics in Medicine.

[369]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[370]  Thomas M. Keane,et al.  POT1 loss-of-function variants predispose to familial melanoma , 2014, Nature Genetics.

[371]  G. Gyapay,et al.  Germline BAP1 mutations predispose to renal cell carcinomas. , 2013, American journal of human genetics.

[372]  M. P. Leòn,et al.  Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors , 2014, Techniques in Coloproctology.

[373]  Yuxin Tang,et al.  TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway , 2016, OncoTargets and therapy.

[374]  Hermann Brenner,et al.  A systematic review of leukocyte telomere length and age in adults , 2013, Ageing Research Reviews.

[375]  A. Fantin,et al.  PET/CT incidental detection of second tumor in patients investigated for pancreatic neoplasms , 2018, BMC Cancer.

[376]  S. Bojesen,et al.  Increased risk of breast cancer associated with CHEK2*1100delC. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[377]  A. Hussain,et al.  Testicular germ cell tumors: biology and clinical update , 2006, Current opinion in oncology.

[378]  Derek W Wright,et al.  Gateways to the FANTOM5 promoter level mammalian expression atlas , 2015, Genome Biology.

[379]  Richard C Trembath,et al.  Germline Mutations in the CDKN2B Tumor Suppressor Gene Predispose to Renal Cell Carcinoma. , 2015, Cancer discovery.

[380]  P. Devilee,et al.  Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation , 2000, The Lancet.